181 related articles for article (PubMed ID: 29169525)
41. A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
Tamiya A; Shimizu S; Atagi S
J Thorac Oncol; 2015 Aug; 10(8):e74. PubMed ID: 26200283
[No Abstract] [Full Text] [Related]
42. Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.
Skoulidis F; Papadimitrakopoulou VA
Clin Cancer Res; 2016 Nov; 22(21):5177-5182. PubMed ID: 27609840
[TBL] [Abstract][Full Text] [Related]
43.
Kelly AD; Wiklund T; Kononen J; Creeden J
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423228
[No Abstract] [Full Text] [Related]
44. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
[TBL] [Abstract][Full Text] [Related]
45. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
[TBL] [Abstract][Full Text] [Related]
46. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
[TBL] [Abstract][Full Text] [Related]
47. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
Ajimizu H; Kim YH; Mishima M
Med Oncol; 2015 Feb; 32(2):477. PubMed ID: 25556163
[TBL] [Abstract][Full Text] [Related]
48. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
49. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Tamura T; Kiura K; Seto T; Nakagawa K; Maemondo M; Inoue A; Hida T; Yoshioka H; Harada M; Ohe Y; Nogami N; Murakami H; Kuriki H; Shimada T; Tanaka T; Takeuchi K; Nishio M
J Clin Oncol; 2017 May; 35(14):1515-1521. PubMed ID: 28296581
[TBL] [Abstract][Full Text] [Related]
50. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract][Full Text] [Related]
51. A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants.
He M; Li W; Zheng Q; Zhang H
J Cell Biochem; 2018 Jul; 119(7):5332-5342. PubMed ID: 29323742
[TBL] [Abstract][Full Text] [Related]
52. Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.
Zhu VW; Lu Y; Ou SI
Clin Lung Cancer; 2019 Jan; 20(1):e77-e80. PubMed ID: 30318176
[No Abstract] [Full Text] [Related]
53. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Larkins E; Blumenthal GM; Chen H; He K; Agarwal R; Gieser G; Stephens O; Zahalka E; Ringgold K; Helms W; Shord S; Yu J; Zhao H; Davis G; McKee AE; Keegan P; Pazdur R
Clin Cancer Res; 2016 Nov; 22(21):5171-5176. PubMed ID: 27413075
[TBL] [Abstract][Full Text] [Related]
54. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM; Noonan S; O'Bryant C; Jimeno A
Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
[TBL] [Abstract][Full Text] [Related]
55. Alectinib in crizotinib-resistant, ALK-positive NSCLC.
Jassem J
Lancet Oncol; 2016 Feb; 17(2):134-135. PubMed ID: 26708154
[No Abstract] [Full Text] [Related]
56. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Arbour KC; Riely GJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
[TBL] [Abstract][Full Text] [Related]
58. Emerging Options After Progression During Crizotinib Therapy.
Peters S
J Clin Oncol; 2016 Mar; 34(7):643-5. PubMed ID: 26712224
[No Abstract] [Full Text] [Related]
59. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
60. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
